Printer Friendly

Concerned about generic drugs? Check the orange book!

Although generic drugs are often a safe and less expensive alternative to brand-name medication, some sold as "generic equivalents" are not doing the job, say University of Florida researchers. Adds Dr. Leslie Hendeles, professor of pharmacy and pediatrics at UF's Health Science Center, "Unfortunately, some generic products are not truly equivalent."

He and his colleagues recently published an article in the American Journal of Hospital Pharmacy identifying drug products that "lack proof of bioequivalence and pose a risk of adverse outcome to the patient." They listed more than 100 products, including some commonly used to treat heart disease, asthma, thyroid disease, and other disorders.

The Food and Drug Administration (FDA) rates generic drugs in its official publication, Approved Drug Products with Therapeutic Equivalence Evaluations, known to pharmacists as "the orange book." Drugs proved to be equivalent receive an A rating; those that do not receive a B rating. If you want to be sure that the generic drug you are receiving has an A rating, ask your pharmacist to check the orange book.

Unfortunately, most over-the-counter medications are sold without proof of equivalency, as are prescription drugs in existence before 1938, when the Food, Drug and Cosmetic Act exempted them from FDA scrutiny.
COPYRIGHT 1993 Benjamin Franklin Literary & Medical Society, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Approved Drug Products with Therapeutic Equivalence Evaluations
Publication:Medical Update
Date:Dec 1, 1993
Words:203
Previous Article:CFS - the great unknown.
Next Article:Preventing recurrences of febrile convulsions in children.
Topics:


Related Articles
Generic vs. brand name.
Consumer class actions follow suits by generic drug makers against brand-name companies.
Spectrum announces initiation of Imitrex injection patent challenge.
Fixing the biotech marketplace: generic biologic drugs could save billions.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters